Antares Pharma Inc (NASDAQ:ATRS) Given Average Rating of “Buy” by Brokerages

Share on StockTwits

Shares of Antares Pharma Inc (NASDAQ:ATRS) have earned a consensus rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $5.04.

Separately, BidaskClub lowered Antares Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, August 20th.

A number of large investors have recently added to or reduced their stakes in the stock. River & Mercantile Asset Management LLP acquired a new position in Antares Pharma during the 2nd quarter valued at approximately $2,603,000. Nuveen Asset Management LLC acquired a new position in Antares Pharma during the 2nd quarter valued at approximately $2,252,000. Jane Street Group LLC acquired a new position in Antares Pharma during the 2nd quarter valued at approximately $362,000. Vanguard Group Inc. boosted its position in Antares Pharma by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 7,419,037 shares of the specialty pharmaceutical company’s stock valued at $24,409,000 after purchasing an additional 110,433 shares during the period. Finally, Private Advisor Group LLC boosted its position in Antares Pharma by 21.2% during the 2nd quarter. Private Advisor Group LLC now owns 125,251 shares of the specialty pharmaceutical company’s stock valued at $412,000 after purchasing an additional 21,871 shares during the period. Institutional investors and hedge funds own 38.73% of the company’s stock.

Shares of ATRS traded down $0.07 during mid-day trading on Tuesday, hitting $3.55. The stock had a trading volume of 1,009,844 shares, compared to its average volume of 858,475. The company has a market cap of $590.28 million, a PE ratio of -88.75 and a beta of 0.90. The company’s fifty day simple moving average is $3.29 and its two-hundred day simple moving average is $3.11. The company has a quick ratio of 2.87, a current ratio of 3.46 and a debt-to-equity ratio of 1.01. Antares Pharma has a fifty-two week low of $2.53 and a fifty-two week high of $3.96.

Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.03. The company had revenue of $28.43 million during the quarter, compared to analyst estimates of $21.66 million. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%. Equities analysts expect that Antares Pharma will post -0.08 earnings per share for the current year.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Read More: Most Active Stocks

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.